Therapeutic & Diagnostic Systems and Technologies Webinar Series | Stuart Campbell, Yale | IEEE EMBS

How close are we to using human engineered heart tissue (EHT) to diagnose cardiomyopathies and guide therapy? In this IEEE EMBS webinar, Prof. Stuart Campbell (Yale University) walks through a decade of research at the intersection of cardiac muscle physiology, multiscale computational modeling, tissue engineering, and clinical cardiology. He shows how iPSC-derived cardiomyocytes grown on decellularized myocardial scaffolds can capture human-relevant mechanics, illuminate genotype→phenotype pathways, and help classify variants of unknown significance (VUS). Using paired TPM1 mutations - E62Q (hypertrophic cardiomyopathy, HCM) and E54K (dilated cardiomyopathy, DCM) - the talk demonstrates opposite effects on force generation, length-dependent activation (Frank-Starling response), diastolic stiffness, and calcium sensitivity. Campbell also shares how mavacamten (myosin inhibitor) and danicamtiv (myosin activator) normalize contractile phenotypes in EHTs, and outlines a practical pipeline to functionally classify patient variants in weeks, plus early evidence that EHTs from “genotype-negative” HCM patients can still reveal contractile abnormalities. What you’ll learn: -How engineered heart tissue is built (iPSC cardiomyocytes on aligned, decellularized ventricular matrix) and measured -Mechanistic differences between HCM and DCM in human-relevant tissue models -The TPM1 E62Q vs E54K case study: force, relaxation, and calcium sensitivity How mavacamten and danicamtiv modulate hyper and hypo-contractility in EHTs -A scalable approach to classifying VUS using EHTs and complementary modeling -Why reference panels matter and how contractile metrics can aid risk stratification Speaker: Stuart Campbell, PhD - Professor of Biomedical Engineering, Yale University; scientific founder of Propria LLC. Host: Therapeutic and Diagnostic Systems & Technology Technical Committee, IEEE EMBS. Keywords: engineered heart tissue, EHT, iPSC cardiomyocytes, hypertrophic cardiomyopathy, dilated cardiomyopathy, TPM1, tropomyosin, genotype to phenotype, Frank-Starling, calcium sensitivity, mavacamten, danicamtiv, VUS classification, cardiac tissue engineering, biomedical engineering Subscribe to the IEEE EMBS channel for more webinars and research talks.